Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma: Results of a 196-patient series.
Prospective studies have reported ongoing remissions in most patients with localized Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma after curing the infection. Using specific selection criteria, the outcome of 196 patients treated in routine clinical practice was analysed. Complete remission rates, stability of remissions and frequency of relapse and histologic residual disease were in accordance with previous prospective clinical trials, whereas the median age was higher. Only a minority had a complete staging, and it may be expected that there is a significant group of patients with an unrecognized higher stage in this cohort. The frequency of follow-up investigations was also not considered as recommended in a considerable number of patients. Nevertheless, the outcome of patients was favourable regardless of limited staging and follow-up procedures. Amended recommendations and special guidelines for elderly and patients with concomitant disease should be considered.
Wündisch
Thomas
T
Klinik für Hämatologie, Onkologie und Immunologie, Klinikum der Philipps Universität, Marburg, Germany. wuendisc@med.uni-marburg.de
Mösch
Christoph
C
Neubauer
Andreas
A
Stolte
Manfred
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000494:pharmacology*; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology*; D016481:Helicobacter Infections / Q000628:therapy*; D016480:Helicobacter pylori / Q000378:metabolism*; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000382:microbiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013270:Stomach / Q000382:microbiology; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000382:microbiology; D013997:Time Factors; D016896:Treatment Outcome
D000890:Anti-Infective Agents